Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposomal + oxaliplatin + tegafur for borderline resectable/locally advanced pancreatic cancer
ChiCTR2500112094Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Nov 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan, oxaliplatin and tegafur in pancreatic adenocarcinoma (PDAC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Event-free survival. Started Nov 2025; status: recruiting.
02
Drugs
nanoliposomal irinotecanoxaliplatintegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2500112094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112094.